Trial comparator supply from Canada
Every trial below uses at least one comparator that is marketed in Canada, which means the comparator can be supplied with the Canadian label, Certificate of Analysis, batch number and expiry documentation, without a Special Access request. Nexara Health supplies comparator, rescue and ancillary medication to sponsors and CROs under Health Canada Drug Establishment Licence #3-002896 from Winnipeg, Manitoba.
Comparator supply fails for predictable reasons: the presentation available locally does not match the protocol, the shortage hits mid-study, or the source market cannot document the chain of custody an auditor expects. Sourcing the comparator from Canada solves the first two and documents the third. The list below is refreshed from the public trial registry; each page shows the marketed Canadian products, the manufacturers behind them, and the strengths that can be supplied.
| NCT | Trial | Comparator | Sponsor | Status | Updated |
|---|---|---|---|---|---|
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M | afatinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT03907488 | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed | vinblastine sulfate | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02152982 | Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | temozolomide | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | etoposide | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02642042 | Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Canc | trametinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT03907488 | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed | doxorubicin hydrochloride | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | cyclophosphamide monohydrate | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02115282 | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That i | goserelin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02306161 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | etoposide | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02455557 | SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | temozolomide | Roswell Park Cancer Institute | Active Not Recruiting | 2026-10-22 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M | sunitinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02642042 | Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Canc | docetaxel | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT03660826 | Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib A | capivasertib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT03907488 | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed | dacarbazine - dtic | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07664852 | Pramipexole vs Placebo Treatment in Bipolar Disorder With Anhedonic Depression | pramipexole | Daniel Lindqvist | Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | cyclophosphamide | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT01886872 | Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Pr | ibrutinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02115282 | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That i | exemestane | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02194738 | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by | erlotinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02306161 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | doxorubicin hydrochloride | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02306161 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | etoposide phosphate | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02446457 | Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diff | lenalidomide | M.D. Anderson Cancer Center | Active Not Recruiting | 2026-10-22 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M | osimertinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M | palbociclib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT04701242 | Ezetimibe Utilization Early After Acute Myocardial Infarction, "EzAMI Trial" | ezetimibe 10mg | Cairo University | Recruiting | 2026-10-22 |
| NCT02466971 | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiati | cisplatin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02947685 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | palbociclib | Alliance Foundation Trials, LLC. | Active Not Recruiting | 2026-10-22 |
| NCT03595124 | A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) | axitinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | bevacizumab | Hoffmann-La Roche | Active Not Recruiting | 2026-10-22 |
| NCT03907488 | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed | dacarbazine | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07581002 | A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Com | azacitidine | AbbVie | Recruiting | 2026-10-22 |
| NCT07662213 | A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semag | semaglutide | AstraZeneca | Recruiting | 2026-10-22 |
| NCT07888621 | Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous Syst | oxaliplatin | The First Affiliated Hospital with Nanjing Medical Universit | Not Yet Recruiting | 2026-10-22 |
| NCT00658814 | Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | gemtuzumab ozogamicin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | methotrexate | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT01886872 | Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Pr | bendamustine hydrochloride | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT01896999 | Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Ly | brentuximab vedotin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02068586 | Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma | valproic acid | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferso | Active Not Recruiting | 2026-10-22 |
| NCT02158091 | A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL | fludarabine | Dana-Farber Cancer Institute | Active Not Recruiting | 2026-10-22 |
| NCT02194738 | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by | crizotinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT03412396 | Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy | apalutamide | M.D. Anderson Cancer Center | Active Not Recruiting | 2026-10-22 |
| NCT02306161 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | doxorubicin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07711483 | GLORY: Glofit-GemOx With Liso-Cel For Lymphoma | obinutuzumab | Massachusetts General Hospital | Recruiting | 2026-10-22 |
| NCT07563738 | A 2-part Phase 1/2 Open-label Trial on ODM-212 | sotorasib | Orion Corporation, Orion Pharma | Recruiting | 2026-10-22 |
| NCT02306161 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | ifosfamide | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02306161 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | vincristine sulfate | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M | dabrafenib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M | larotrectinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07783425 | A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema | dupilumab | Pfizer | Recruiting | 2026-10-22 |
| NCT07775313 | Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM | plerixafor | National Institute of Allergy and Infectious Diseases (NIAID | Enrolling By Invitation | 2026-10-22 |
| NCT07883226 | A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions | itraconazole | Gates Medical Research Institute | Recruiting | 2026-10-22 |
| NCT07882173 | Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosin | epcoritamab | National Heart, Lung, and Blood Institute (NHLBI) | Not Yet Recruiting | 2026-10-22 |
| NCT07883538 | Comparison of Topical Clascoterone 1% Cream Versus Adapalene 0.1% Cream in the Treatment of Mild-to-Moderate Acne Vulgar | clascoterone 1% cream | Pak Emirates Military Hospital | Recruiting | 2026-10-22 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M | vismodegib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02912559 | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA | oxaliplatin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02947685 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | letrozole | Alliance Foundation Trials, LLC. | Active Not Recruiting | 2026-10-22 |
| NCT03191149 | Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change | osimertinib | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT03491683 | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Gli | temozolomide | Inovio Pharmaceuticals | Active Not Recruiting | 2026-10-22 |
| NCT03709758 | Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML | cytarabine | Dana-Farber Cancer Institute | Active Not Recruiting | 2026-10-22 |
| NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | doxorubicin hydrochloride | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | pembrolizumab | Hoffmann-La Roche | Active Not Recruiting | 2026-10-22 |
| NCT03907488 | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed | brentuximab vedotin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07572136 | Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/T | cyclophosphamide | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT07572136 | Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/T | fludarabine | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT07629089 | VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations | lomustine | Megan Mantica | Not Yet Recruiting | 2026-10-22 |
| NCT07633600 | Phenotype Guided Vasoactive Medication During Kidney Transplantation | vasopressin | Jennifer Cutler | Enrolling By Invitation | 2026-10-22 |
| NCT07888595 | Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks | metformin | Frontiers in Bioscience Research Institute and Aging | Enrolling By Invitation | 2026-10-22 |
| NCT07888621 | Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous Syst | obinutuzumab | The First Affiliated Hospital with Nanjing Medical Universit | Not Yet Recruiting | 2026-10-22 |
| NCT07889232 | Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer | carboplatin plus pemetrexed; carboplatin plus taxane | VA Office of Research and Development | Not Yet Recruiting | 2026-10-22 |
| NCT00658814 | Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | gemtuzumab | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | dasatinib monohydrate | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | leucovorin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT01064648 | Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothel | cisplatin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT01306019 | Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodefic | busulfan | National Institute of Allergy and Infectious Diseases (NIAID | Recruiting | 2026-10-22 |
| NCT05651932 | A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | pomalidomide | K36 Therapeutics, Inc. | Recruiting | 2026-10-22 |
| NCT05651932 | A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | dexamethasone | K36 Therapeutics, Inc. | Recruiting | 2026-10-22 |
| NCT02068586 | Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma | sunitinib | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferso | Active Not Recruiting | 2026-10-22 |
| NCT02068586 | Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma | sunitinib malate + valproic acid | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferso | Active Not Recruiting | 2026-10-22 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | doxorubicin hydrochloride | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT02158091 | A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL | cyclophosphamide | Dana-Farber Cancer Institute | Active Not Recruiting | 2026-10-22 |
| NCT02194738 | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by | carboplatin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02194738 | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by | cisplatin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07524530 | Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers | busulfan | National Cancer Institute (NCI) | Not Yet Recruiting | 2026-10-22 |
| NCT02194738 | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by | paclitaxel | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02196181 | Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread | trametinib dimethyl sulfoxide | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02306161 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | cyclophosphamide monohydrate | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07672483 | IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors | cetuximab | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT07524530 | Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers | tacrolimus | National Cancer Institute (NCI) | Not Yet Recruiting | 2026-10-22 |
| NCT07549490 | Human Experimental Models of Pain (HEMP) | naproxen | National Center for Complementary and Integrative Health (NC | Not Yet Recruiting | 2026-10-22 |
| NCT07563738 | A 2-part Phase 1/2 Open-label Trial on ODM-212 | ipilimumab and nivolumab | Orion Corporation, Orion Pharma | Recruiting | 2026-10-22 |
| NCT07711483 | GLORY: Glofit-GemOx With Liso-Cel For Lymphoma | lisocabtagene maraleucel | Massachusetts General Hospital | Recruiting | 2026-10-22 |
| NCT07673887 | A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer | capecitabine | Astellas Pharma Global Development, Inc. | Recruiting | 2026-10-22 |
| NCT07711483 | GLORY: Glofit-GemOx With Liso-Cel For Lymphoma | glofitamab | Massachusetts General Hospital | Recruiting | 2026-10-22 |
| NCT02306161 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | vincristine | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M | binimetinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M | crizotinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M | dasatinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M | erdafitinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07890493 | Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung | carboplatin | Canadian Cancer Trials Group | Not Yet Recruiting | 2026-10-22 |
| NCT07751848 | A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus | anifrolumab | AstraZeneca | Recruiting | 2026-10-22 |
| NCT07753252 | Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body | sevabertinib | Bayer | Recruiting | 2026-10-22 |
| NCT07775313 | Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM | filgrastim | National Institute of Allergy and Infectious Diseases (NIAID | Enrolling By Invitation | 2026-10-22 |
| NCT07850934 | Effect of Melatonin on Pulmonary Hypertension in Full Term Neonates | melatonin | Ain Shams University | Recruiting | 2026-10-22 |
| NCT07827599 | A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza V | baloxavir marboxil | Hoffmann-La Roche | Recruiting | 2026-10-22 |
| NCT05834777 | Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor | icatibant | Vanderbilt University Medical Center | Active Not Recruiting | 2026-10-22 |
| NCT07876414 | A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck | pembrolizumab | Groupe Oncologie Radiotherapie Tete et Cou | Not Yet Recruiting | 2026-10-22 |
| NCT07888569 | Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21) | rabeprazole | Dizal Pharmaceuticals | Not Yet Recruiting | 2026-10-22 |
| NCT07883538 | Comparison of Topical Clascoterone 1% Cream Versus Adapalene 0.1% Cream in the Treatment of Mild-to-Moderate Acne Vulgar | adapalene 0.1% cream | Pak Emirates Military Hospital | Recruiting | 2026-10-22 |
| NCT07887984 | Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple M | bortezomib | Alliance for Clinical Trials in Oncology | Not Yet Recruiting | 2026-10-22 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M | trametinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02839707 | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent O | doxorubicin hydrochloride liposome | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02912559 | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA | leucovorin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02947685 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | anastrozole | Alliance Foundation Trials, LLC. | Active Not Recruiting | 2026-10-22 |
| NCT02947685 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | fulvestrant | Alliance Foundation Trials, LLC. | Active Not Recruiting | 2026-10-22 |
| NCT03114865 | A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | blinatumomab | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active Not Recruiting | 2026-10-22 |
| NCT03114865 | A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | dexamethasone | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active Not Recruiting | 2026-10-22 |
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | dabrafenib | Novartis Pharmaceuticals | Recruiting | 2026-10-22 |
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | trametinib | Novartis Pharmaceuticals | Recruiting | 2026-10-22 |
| NCT03701282 | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leu | ibrutinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT03701282 | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leu | venetoclax | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT03737981 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untre | ibrutinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | atezolizumab | Hoffmann-La Roche | Active Not Recruiting | 2026-10-22 |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | cobimetinib | Hoffmann-La Roche | Active Not Recruiting | 2026-10-22 |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | paclitaxel | Hoffmann-La Roche | Active Not Recruiting | 2026-10-22 |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | vemurafenib | Hoffmann-La Roche | Active Not Recruiting | 2026-10-22 |
| NCT03811015 | Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer | cisplatin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07728097 | A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS | cannabidiol oral solution | Jazz Pharmaceuticals | Not Yet Recruiting | 2026-10-22 |
| NCT00588770 | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell C | docetaxel | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07890493 | Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung | paclitaxel | Canadian Cancer Trials Group | Not Yet Recruiting | 2026-10-22 |
| NCT06769698 | A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Meta | cemiplimab | Regeneron Pharmaceuticals | Recruiting | 2026-10-22 |
| NCT07581002 | A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Com | venetoclax | AbbVie | Recruiting | 2026-10-22 |
| NCT07621484 | HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer | oxaliplatin | Shanghai Changzheng Hospital | Recruiting | 2026-10-22 |
| NCT07633600 | Phenotype Guided Vasoactive Medication During Kidney Transplantation | calcium chloride | Jennifer Cutler | Enrolling By Invitation | 2026-10-22 |
| NCT07633600 | Phenotype Guided Vasoactive Medication During Kidney Transplantation | norepinephrine | Jennifer Cutler | Enrolling By Invitation | 2026-10-22 |
| NCT07775313 | Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM | busulfan | National Institute of Allergy and Infectious Diseases (NIAID | Enrolling By Invitation | 2026-10-22 |
| NCT07888595 | Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks | ivermectin | Frontiers in Bioscience Research Institute and Aging | Enrolling By Invitation | 2026-10-22 |
| NCT07888621 | Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous Syst | gemcitabine | The First Affiliated Hospital with Nanjing Medical Universit | Not Yet Recruiting | 2026-10-22 |
| NCT07888621 | Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous Syst | glofitamab | The First Affiliated Hospital with Nanjing Medical Universit | Not Yet Recruiting | 2026-10-22 |
| NCT07888933 | Intravenous Ketamine for Acute Suicidal Crisis and Psychiatric Hospital Length of Stay | esketamine | University of Sao Paulo | Not Yet Recruiting | 2026-10-22 |
| NCT07889115 | Evaluation of the Effect of Amantadine in the Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Pa | amantadine | Al-Azhar University | Not Yet Recruiting | 2026-10-22 |
| NCT07889687 | This Study is Comparing Pain Outcomes After Urethral Bulking When Participants Are Randomized to Two Different Pain Medi | lidocaine injection | Northwell Health | Recruiting | 2026-10-22 |
| NCT00658814 | Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | azacitidine | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | dasatinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | dasatinib hydrate | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | dexamethasone intensol | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | etoposide | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT00972478 | Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or St | prednisone | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT00972478 | Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or St | vorinostat | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT01272037 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive | exemestane | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT01272037 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive | letrozole | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07475806 | A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep | enfortumab vedotin | Astellas Pharma Global Development, Inc. | Recruiting | 2026-10-22 |
| NCT07475286 | Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomat | mitomycin c | Mohammad Haroon Asif Choudry | Recruiting | 2026-10-22 |
| NCT05638295 | Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers | sotorasib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT05651932 | A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | carfilzomib | K36 Therapeutics, Inc. | Recruiting | 2026-10-22 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | cyclophosphamide | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | brentuximab vedotin | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | cyclophosphamide monohydrate | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT02068586 | Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma | sunitinib malate | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferso | Active Not Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | sirolimus | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | dacarbazine - dtic | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT07524530 | Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers | cyclophosphamide | National Cancer Institute (NCI) | Not Yet Recruiting | 2026-10-22 |
| NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Art | carfilzomib | National Cancer Institute (NCI) | Not Yet Recruiting | 2026-10-22 |
| NCT07887984 | Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple M | lenalidomide | Alliance for Clinical Trials in Oncology | Not Yet Recruiting | 2026-10-22 |
| NCT02158091 | A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL | rituximab | Dana-Farber Cancer Institute | Active Not Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | methotrexate lpf | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02194738 | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by | carboplatin hexal | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | methotrexate methylaminopterin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | methylprednisolone | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07520006 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | obinutuzumab | Nurix Therapeutics, Inc. | Recruiting | 2026-10-22 |
| NCT07520006 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | rituximab | Nurix Therapeutics, Inc. | Recruiting | 2026-10-22 |
| NCT07520006 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | venetoclax | Nurix Therapeutics, Inc. | Recruiting | 2026-10-22 |
| NCT02194738 | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by | pemetrexed | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02224781 | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Tr | trametinib dimethyl sulfoxide | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02306161 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | cyclophosphamide | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07888309 | SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advance | fruquintinib | Ruijin Hospital | Recruiting | 2026-10-22 |
| NCT07535905 | Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patie | tamoxifen | University Health Network, Toronto | Recruiting | 2026-10-22 |
| NCT07524530 | Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers | fludarabine | National Cancer Institute (NCI) | Not Yet Recruiting | 2026-10-22 |
| NCT07524530 | Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers | mycophenolate mofetil | National Cancer Institute (NCI) | Not Yet Recruiting | 2026-10-22 |
| NCT07887984 | Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple M | melphalan | Alliance for Clinical Trials in Oncology | Not Yet Recruiting | 2026-10-22 |
| NCT07887984 | Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple M | teclistamab | Alliance for Clinical Trials in Oncology | Not Yet Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | prednisone intensol | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07549490 | Human Experimental Models of Pain (HEMP) | pregabalin | National Center for Complementary and Integrative Health (NC | Not Yet Recruiting | 2026-10-22 |
| NCT07672483 | IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors | cyclophosphamide | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT07673887 | A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer | oxaliplatin | Astellas Pharma Global Development, Inc. | Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | prednisone | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07672483 | IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors | fludarabine | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT07686770 | Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease | acetylsalicylic acid | Children's Hospital of Fudan University | Not Yet Recruiting | 2026-10-22 |
| NCT07673887 | A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer | pembrolizumab | Astellas Pharma Global Development, Inc. | Recruiting | 2026-10-22 |
| NCT07711483 | GLORY: Glofit-GemOx With Liso-Cel For Lymphoma | fludarabine | Massachusetts General Hospital | Recruiting | 2026-10-22 |
| NCT07711483 | GLORY: Glofit-GemOx With Liso-Cel For Lymphoma | cyclophosphamide | Massachusetts General Hospital | Recruiting | 2026-10-22 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | etoposide phosphate | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT07796360 | Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast | gadobutrol | National Institute of Neurological Disorders and Stroke (NIN | Not Yet Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | vincristine sulfate | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M | capivasertib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | prednisolone | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | prednisone | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M | dasatinib hydrate | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M | dasatinib monohydrate | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT06653400 | Combined Ketorolac and Lidocaine Paracervical Block for Office Hysteroscopy | lidocaine | Icahn School of Medicine at Mount Sinai | Enrolling By Invitation | 2026-10-22 |
| NCT07890064 | Canagliflozin Plus Progestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial Cancer | metformin | Wang Yingmei | Not Yet Recruiting | 2026-10-22 |
| NCT00972478 | Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or St | cyclophosphamide | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07748039 | Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events | tenecteplase | Yongjun Wang | Recruiting | 2026-10-22 |
| NCT00972478 | Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or St | cyclophosphamide monohydrate | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07753252 | Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body | metformin | Bayer | Recruiting | 2026-10-22 |
| NCT07756840 | Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) | bevacizumab | National Cancer Institute (NCI) | Not Yet Recruiting | 2026-10-22 |
| NCT00588770 | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell C | carboplatin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07888595 | Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks | hydroxychloroquine | Frontiers in Bioscience Research Institute and Aging | Enrolling By Invitation | 2026-10-22 |
| NCT06096844 | Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The | paclitaxel albumin | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | prednisone intensol | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT07808151 | Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer | pembrolizumab | Solstice Oncology, Inc. | Recruiting | 2026-10-22 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | vincristine sulfate | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | vinblastine sulfate | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT05713799 | Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity | mirabegron | National Institute of Diabetes and Digestive and Kidney Dise | Not Yet Recruiting | 2026-10-22 |
| NCT05711615 | Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Adv | doxorubicin hydrochloride liposome | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT06096844 | Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The | paclitaxel albumin-stabilized nanoparticle formulation | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT06096844 | Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The | paclitaxel nanoparticle albumin-bound | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT07888309 | SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advance | tislelizumab | Ruijin Hospital | Recruiting | 2026-10-22 |
| NCT07888335 | Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions | obinutuzumab beta | Ruijin Hospital | Not Yet Recruiting | 2026-10-22 |
| NCT06096844 | Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The | paclitaxel protein-bound | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT06096844 | Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The | pemetrexed | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT00588770 | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell C | carboplatin hexal | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M | sunitinib malate | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT03793179 | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell | carboplatin hexal | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02839707 | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent O | atezolizumab | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02912559 | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA | atezolizumab | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT02912559 | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA | fluorouracil | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07890220 | Intravenous Dexamethasone for ESP Block Analgesia in Children Undergoing Idiopathic Scoliosis Surgery | dexamethasone | Poznan University of Medical Sciences | Not Yet Recruiting | 2026-10-22 |
| NCT06449339 | Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease | carvedilol | Chinese University of Hong Kong | Recruiting | 2026-10-22 |
| NCT06465069 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | pembrolizumab | Eli Lilly and Company | Recruiting | 2026-10-22 |
| NCT02947685 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | exemestane | Alliance Foundation Trials, LLC. | Active Not Recruiting | 2026-10-22 |
| NCT02947685 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | pertuzumab | Alliance Foundation Trials, LLC. | Active Not Recruiting | 2026-10-22 |
| NCT02947685 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | trastuzumab | Alliance Foundation Trials, LLC. | Active Not Recruiting | 2026-10-22 |
| NCT03114865 | A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | blinatumomab 28 ug | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active Not Recruiting | 2026-10-22 |
| NCT03114865 | A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | blinatumomab 9ug | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active Not Recruiting | 2026-10-22 |
| NCT03228537 | Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With St | atezolizumab | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT03228537 | Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With St | cisplatin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT06467526 | Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss | hydroxychloroquine | Chang Gung Memorial Hospital | Recruiting | 2026-10-22 |
| NCT06483074 | Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients | empagliflozin 10 mg | Chinese University of Hong Kong | Recruiting | 2026-10-22 |
| NCT06626919 | Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases | fludarabine | Kite, A Gilead Company | Recruiting | 2026-10-22 |
| NCT03660826 | Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib A | olaparib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT06626919 | Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases | cyclophosphamide | Kite, A Gilead Company | Recruiting | 2026-10-22 |
| NCT06616532 | PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer | topotecan | Biotheus Inc. | Active Not Recruiting | 2026-10-22 |
| NCT03709758 | Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML | daunorubicin | Dana-Farber Cancer Institute | Active Not Recruiting | 2026-10-22 |
| NCT03709758 | Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML | venetoclax | Dana-Farber Cancer Institute | Active Not Recruiting | 2026-10-22 |
| NCT03737981 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untre | venetoclax | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | alectinib | Hoffmann-La Roche | Active Not Recruiting | 2026-10-22 |
| NCT03793166 | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advan | cabozantinib | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | cabozantinib | Hoffmann-La Roche | Active Not Recruiting | 2026-10-22 |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | enzalutamide | Hoffmann-La Roche | Active Not Recruiting | 2026-10-22 |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | niraparib | Hoffmann-La Roche | Active Not Recruiting | 2026-10-22 |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | pemetrexed | Hoffmann-La Roche | Active Not Recruiting | 2026-10-22 |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | sunitinib | Hoffmann-La Roche | Active Not Recruiting | 2026-10-22 |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | venetoclax | Hoffmann-La Roche | Active Not Recruiting | 2026-10-22 |
| NCT03793179 | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell | pemetrexed | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07890493 | Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung | pembrolizumab | Canadian Cancer Trials Group | Not Yet Recruiting | 2026-10-22 |
| NCT07890714 | A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)] | pembrolizumab | Daiichi Sankyo | Recruiting | 2026-10-22 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | etoposide | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT00588770 | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell C | cisplatin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT06790095 | TRACK-TBI Precision Medicine Part 3 - Option II | cyclosporine | University of California, San Francisco | Enrolling By Invitation | 2026-10-22 |
| NCT07887984 | Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple M | dexamethasone | Alliance for Clinical Trials in Oncology | Not Yet Recruiting | 2026-10-22 |
| NCT06653400 | Combined Ketorolac and Lidocaine Paracervical Block for Office Hysteroscopy | ketorolac | Icahn School of Medicine at Mount Sinai | Enrolling By Invitation | 2026-10-22 |
| NCT06745063 | Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity | empagliflozin | VA Office of Research and Development | Recruiting | 2026-10-22 |
| NCT07890493 | Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung | pemetrexed | Canadian Cancer Trials Group | Not Yet Recruiting | 2026-10-22 |
| NCT07890714 | A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)] | enfortumab vedotin | Daiichi Sankyo | Recruiting | 2026-10-22 |
| NCT07619521 | Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic | selumetinib | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT07621484 | HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer | capecitabine | Shanghai Changzheng Hospital | Recruiting | 2026-10-22 |
| NCT07890571 | COMPARISON OF TOPICAL VITAMIN C VS NIACINAMIDE IN TREATMENT OF MELASMA | ascorbic acid 10 % | Pak Emirates Military Hospital | Not Yet Recruiting | 2026-10-22 |
| NCT07629089 | VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations | vorasidenib | Megan Mantica | Not Yet Recruiting | 2026-10-22 |
| NCT07890571 | COMPARISON OF TOPICAL VITAMIN C VS NIACINAMIDE IN TREATMENT OF MELASMA | ascorbic acid | Pak Emirates Military Hospital | Not Yet Recruiting | 2026-10-22 |
| NCT03793179 | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell | carboplatin | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT04579224 | Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothel | paclitaxel | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT07887984 | Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple M | daratumumab and recombinant human hyaluronidase | Alliance for Clinical Trials in Oncology | Not Yet Recruiting | 2026-10-22 |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | irinotecan | Artios Pharma Ltd | Recruiting | 2026-10-22 |
| NCT07667335 | Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Ur | enfortumab vedotin | Fred Hutchinson Cancer Center | Recruiting | 2026-10-22 |
| NCT04579224 | Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothel | eribulin mesylate | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | tacrolimus | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT04579224 | Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothel | docetaxel | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT04545736 | Oral Metformin for Treatment of ABCA4 Retinopathy | metformin hydrochloride | National Eye Institute (NEI) | Active Not Recruiting | 2026-10-22 |
| NCT07888647 | IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas | imiquimod 5 % cream | German Cancer Research Center | Not Yet Recruiting | 2026-10-22 |
| NCT07888647 | IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas | temozolomide | German Cancer Research Center | Not Yet Recruiting | 2026-10-22 |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | gemcitabine | Artios Pharma Ltd | Recruiting | 2026-10-22 |
| NCT07888933 | Intravenous Ketamine for Acute Suicidal Crisis and Psychiatric Hospital Length of Stay | midazolam | University of Sao Paulo | Not Yet Recruiting | 2026-10-22 |
| NCT07889232 | Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer | pembrolizumab | VA Office of Research and Development | Not Yet Recruiting | 2026-10-22 |
| NCT07889232 | Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer | tocilizumab | VA Office of Research and Development | Not Yet Recruiting | 2026-10-22 |
| NCT07890064 | Canagliflozin Plus Progestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial Cancer | canagliflozin | Wang Yingmei | Not Yet Recruiting | 2026-10-22 |
| NCT00588770 | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell C | fluorouracil | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | dacarbazine | National Cancer Institute (NCI) | Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | cytarabine | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT04682158 | Propranolol With Chemotherapy or Chemoradiation for Esophageal Adenocarcinoma | carboplatin | Roswell Park Cancer Institute | Recruiting | 2026-10-22 |
| NCT04682158 | Propranolol With Chemotherapy or Chemoradiation for Esophageal Adenocarcinoma | paclitaxel | Roswell Park Cancer Institute | Recruiting | 2026-10-22 |
| NCT06978439 | Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease | rivaroxaban | Children's Hospital of Fudan University | Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | dexamethasone | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukem | doxorubicin hydrochloride | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT04682158 | Propranolol With Chemotherapy or Chemoradiation for Esophageal Adenocarcinoma | propranolol | Roswell Park Cancer Institute | Recruiting | 2026-10-22 |
| NCT07475286 | Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomat | cisplatin | Mohammad Haroon Asif Choudry | Recruiting | 2026-10-22 |
| NCT00972478 | Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or St | doxorubicin hydrochloride | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT00972478 | Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or St | prednisone intensol | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT00972478 | Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or St | vincristine sulfate | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT01272037 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive | anastrozole | National Cancer Institute (NCI) | Active Not Recruiting | 2026-10-22 |
| NCT03955172 | Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated | everolimus | Hospices Civils de Lyon | Recruiting | 2026-10-22 |
Request a quote
Nexara Health is a Health Canada–licensed pharmaceutical wholesaler (DEL #3-002896) based in Winnipeg, Manitoba, supplying hospitals, pharmacies, clinics, CROs, and trial sponsors across Canada. Send us the product, strength, presentation, and quantity for clinical trial comparator supply and we will come back with availability, source market, lead time, and landed cost — usually within 24 hours.
Request a sourcing quote or call +1 (431) 588-9055.